GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytokinetics Inc (STU:KK3A) » Definitions » Other Operating Expense

Cytokinetics (STU:KK3A) Other Operating Expense : €0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cytokinetics Other Operating Expense?

Cytokinetics's Other Operating Expense for the three months ended in Jun. 2024 was €0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2024 was €0.00 Mil.

Cytokinetics's quarterly Other Operating Expense increased from Dec. 2023 (€-0.00 Mil) to Mar. 2024 (€0.00 Mil) and increased from Mar. 2024 (€0.00 Mil) to Jun. 2024 (€0.00 Mil).

Cytokinetics's annual Other Operating Expense increased from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€0.00 Mil) but then declined from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).


Cytokinetics Other Operating Expense Historical Data

The historical data trend for Cytokinetics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytokinetics Other Operating Expense Chart

Cytokinetics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cytokinetics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Cytokinetics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cytokinetics Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Cytokinetics's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Cytokinetics Business Description

Traded in Other Exchanges
Address
350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Cytokinetics Headlines

No Headlines